A number of other research analysts have also recently weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, May 8th. ValuEngine upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Intra-Cellular Therapies currently has a consensus rating of “Hold” and an average price target of $27.60.
Shares of ITCI stock opened at $10.65 on Monday. Intra-Cellular Therapies has a fifty-two week low of $10.21 and a fifty-two week high of $23.62. The firm has a market capitalization of $587.00 million, a PE ratio of -3.75 and a beta of 1.34. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.59 and a quick ratio of 9.59.
In related news, Director Christopher D. Alafi acquired 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average price of $12.56 per share, for a total transaction of $1,256,000.00. Following the transaction, the director now owns 750,106 shares in the company, valued at approximately $9,421,331.36. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 17.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its position in Intra-Cellular Therapies by 883.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,361 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 9,307 shares in the last quarter. First Mercantile Trust Co. increased its position in Intra-Cellular Therapies by 12.3% during the 1st quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 1,265 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth about $142,000. Metropolitan Life Insurance Co. NY increased its position in Intra-Cellular Therapies by 354.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,016 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 10,934 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Intra-Cellular Therapies by 9.4% during the 4th quarter. Legal & General Group Plc now owns 16,044 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 1,374 shares in the last quarter. Hedge funds and other institutional investors own 69.15% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.